<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The revised WHO classification of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of hematopoietic and lymphoid tissues (4th edition) was published in 2008 </plain></SENT>
<SENT sid="1" pm="."><plain>A number of information from molecular biology was introduced, new patterns of classification were proposed, and specific molecular diagnostics and molecular-targeting therapy were introduced in a part of these diseases </plain></SENT>
<SENT sid="2" pm="."><plain>In this symposium, four remarkable points of the WHO-2008 classification (myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> and JAK2 mutation, approaches to <z:e sem="disease" ids="C1540912" disease_type="Neoplastic Process" abbrv="">hypereosinophilic syndromes</z:e>, <z:mp ids='MP_0000002'>morphology</z:mp> of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, and varied classification of lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>) were presented by the expert speakers, and the better understanding of the revised classification is warranted </plain></SENT>
</text></document>